Age-Related Macular Degeration (AMD) Top 10

  1. Can a treatment to stop dry AMD progressing and/or developing into the wet form be devised?
  2. What is the cause of AMD?
  3. How can AMD be prevented?
  4. Are there ways of restoring sight loss for people with AMD?
  5. Can the development of AMD be predicted?
  6. What is the most effective way to detect and monitor the progression of early AMD?
  7. What factors influence the progression of AMD?
  8. Can a non-invasive therapy be developed for wet AMD?
  9. Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD?
  10. What are the best enablement strategies for people with AMD?

The following questions were also discussed and put in order of priority at the workshop:

  1. What is the prospect of developing a screening programme for early detection of AMD?
  2. How effective and safe are current treatments for wet AMD?
  3. Does cataract surgery influence the development/progression of AMD?
  4. How can anti-VEGF treatments e.g. Lucentis be tailored to specific genetic markers predictive for the development of wet AMD?
  5. Is AMD affected by statins?
  6. What is the effectiveness of combining intravitreal steroids with anti-VEGF compared to ani-VEGF treatment alone for patients with wet AMD?
  7. Can donor eyes, or their components, ever be used to restore vision for people with AMD?
  8. What is the best way to assess responses to anti-VEGF treatments for people with wet AMD?
  9. What causes Charles Bonnet syndrome? 

Document downloads

For full details of all of the questions identified, please see the document below.